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Available online 30 March 2016Background:Although in vivo studies have implicated endocannabinoids inmetabolic dysfunction, little is known
about direct, chronic activation of the endocannabinoid system (ECS) in human islets. Therefore, this study inves-
tigated the effects of prolonged exposure to cannabinoid agonists on human islet gene expression and function.
Methods: Human islets were maintained for 2 and 5 days in the absence or presence of CB1r (ACEA) or CB2r
(JWH015) agonists. Gene expression was quantiﬁed by RT-PCR, hormone levels by radioimmunoassay and apo-
ptosis by caspase activities.
Results:Human islets express an ECS, withmRNAs encoding the biosynthetic and degrading enzymes NAPE-PLD,
FAAH andMAGL being considerably more abundant than DAGLα, an enzyme involved in 2-AG synthesis, or CB1
and CB2 receptormRNAs. Prolonged activation of CB1r and CB2r altered expression ofmRNAs encoding ECS com-
ponents, but did not havemajor effects on islet hormone secretion. JWH015 enhanced insulin and glucagon con-
tent at 2 days, but had no effect after 5 days. Treatment with ACEA or JWH015 for up to 5 days did not have
marked effects on islet viability, as assessed by morphology and caspase activities.
Conclusions:Maintenance of human islets for up to 5 days in the presence of CB1 andCB2 receptor agonists causes
modiﬁcations in ECS element gene expression, but does not have any major impact on islet function or viability.
General Signiﬁcance: These data suggest that themetabolic dysfunction associatedwith over-activation of the ECS
in obesity and diabetes in humans is unlikely to be secondary to impaired islet function.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Apoptosis1. Introduction
Islets of Langerhans have a limited capacity to adapt to different envi-
ronmental challenges such as hyperglycaemia, hyperlipidaemia, pregnan-
cy and obesity. When this narrow threshold is insufﬁcient to compensate
for alterations inmetabolic state, inadequateβ-cell turnover and islet dys-
function may lead to the development of type 2 diabetes. In this context,
accumulating evidence suggests that the endocannabinoid system
(ECS) may be involved in the dysregulation of fuel homeostasis
through the hypersecretion of the endocannabinoids anandamide (AEA)
and2-arachidonoyl glycerol (2-AG) fromexpanding adipocytes in obesity4Z-eiscosatetraenamide; AEA,
abinoid receptor type 1; CB2r,
ECS, endocannabinoid system;
yl-1propyl-1H-indol-3-yl)-1-
NAPE-PLD, N-acyl-phosphatidyl
glucagon; PPI, preproinsulin.
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).
. This is an open access article under[1–8]. Sustained elevations in endocannabinoid levels in the circulation
that occur following ECS over-activation in obese and diabetic patients
are reported to have detrimental effects in peripheral organs, leading to
impaired insulin sensitivity, glucose intolerance and dyslipidaemia [3,4,
7,9,10]. In addition, central CB1 receptor activation by endocannabinoids
has orexigenic effects [11–14], and chronic exposure to cannabinoids is
reported to lead to changes in the expression of lipogenic genes and
lipid content in hepatocytes [4,15,16], and to the induction of apoptosis
in sebocytes [5].
Rodent and human islets express a local ECS consisting of the en-
zymes required for the synthesis (NAPE-PLD and DAGL) and degrada-
tion (FAAH and MAGL) of AEA and 2-AG, and the endocannabinoids
can activate the CB1 and CB2 cannabinoid receptors that are also
expressed by islet cells [10,17–35]. There is some controversy over
whether acute activation of CB1 and CB2 receptors is coupled to stimu-
lation [17,19,23–27,29–31,33,34], or inhibition [10,18,22,28,32] of insu-
lin secretion from rodent islets. However, our earlier studies in isolated
human islets indicate that CB1 and CB2 receptor agonists can stimulate
insulin secretion [17,30], suggesting that cannabinoids may have bene-
ﬁcial effects in human β-cells. Most studies investigating the effects ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Primer sequences and annealing temperatures used in real-time PCR.
Gene name for Homo sapiens Primer sequences Annealing
temp.
Cannabinoid receptor 1 (CB1r) F 5′-CACCTTCCGCACCATC
ACCAC-3′
60 °C
R 5′-GTCTCCCGCAGTCA
TCTTCTCTTG-3′
Cannabinoid receptor 2 (CB2r) F 5′-CATGGAGGAATGCT
GGGTGAC-3′
62 °C
R 5′-GAGGAAGGCGATGA
ACAGGAG-3′
Diacylglycerol lipase alpha (DAGLα) F 5′-AGAATGTCACCCTC
GGAATGG-3′
62 °C
R 5′-GTGGCTCTCAGCTT
GACAAAGG-3′
Monoacylglycerol lipase (MAGL) F 5′-CAAGGCCCTCATCTTT
GTGT-3′
60 °C
R 5′-ACGTGGAAGTCAGA
CACTAC-3′
Fatty acid amide hydrolase (FAAH) F 5′-CCCAGATGGAACAT
TACAGG-3′
60 °C
R 5′-CAGGATGACTGGTT
TTCAGG-3′
N-acyl phosphatidylethanolamine
phospholipase D (NAPE-PLD)
F 5′-CACGGTAATGGTGG
AAATGG-3′
62 °C
R 5′-GTCCAGATGGTCAT
AGTGGTTG-3′
18s rRNA F 5′-GGGAGCCTGAGAAA
CGG-3′
60 °C
R 5′-GGGTCGGGAGTGGG
TAATTT-3′
Preproinsulin Qiagen Quantitect primer 60 °C
Preproglucagon Qiagen Quantitect primer 60 °C
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cused on acute signalling [10,18,19,22,23,25–34], but 2-AG and AEA
levels are chronically elevated in the pancreas under conditions of
diet-induced obesity [6,25], and these endocannabinoids are also in-
creased in human islets in response to high glucose concentrations [3,
10]. Excess endocannabinoid production by the local islet ECS in obesity
and diabetes could therefore have a chronic impact on islet function
[35].
We have previously evaluated the long term effects of mouse islet
CB1r or CB2r over-activation on ECS gene expression, on insulin and
glucagon secretion and on islet viability, and found that there were no
major functional effects [24]. However, similar studies on the effects of
chronic exposure of human islets to cannabinoids have not been carried
out although cannabinoids have been implicated in mouse β-cell death
[22]. Therefore, the aimof the current studywas to identifywhether iso-
lated human islets maintained chronically with cannabinoid agonists
show modiﬁcations in expression of genes coding for elements of the
ECS, and/or alterations in islet secretory function and viability.
2. Materials and methods
2.1. Materials
DMEM (5.5 mM glucose), penicillin/streptomycin, L-glutamine, col-
lagenase (Type XI), and PCR primers for human CB1r, CB2r, MAGL,
NAPE-PLD, FAAH, DAGL and 18s rRNA were purchased from Sigma Al-
drich (Dorset, UK). Primers for human preproinsulin and
preproglucagon, RNeasy mini kits, and QuantiFast SYBR Green PCR Kit,
were obtained from Qiagen (West Sussex, UK). Real-time PCR master
mix and plates were purchased from Roche Diagnostics Ltd. (West Sus-
sex, UK). N-(2-chloroethyl)-5Z,8Z,11Z,14Z-eiscosatetraenamide (ACEA)
and (2-methyl-1propyl-1H-indol-3-yl)-1-napthalenylmethanone
(JWH015) were from Tocris Biosciences (Bristol, UK). Fetal bovine
serum and reverse transcription reagents were purchased from
Invitrogen (Paisley, UK), and Caspase-3/7-Glo apoptosis kits were ob-
tained from Promega UK (Southampton, UK).
2.2. Human islet exposure to cannabinoids
Human islets were isolated and puriﬁed from non-diabetic, heart-
beating donors (with ethical permission) by the King's College Islet
Transplantation Unit, as previously reported [36]. Human islets from
eight separate donors with the following characteristics were used in
this study: 5 male, 3 female; age 45 ± 4.2; BMI 27 ± 1.0. Hand-
picked, size-matched islets were maintained in culture with DMEM
containing 5.5 mM glucose, 10% FBS, 2 mM L-glutamine, and
100 units/ml penicillin/100 μg/ml streptomycin, for 2 or 5 days in the
presence or absence of either 100 nM of the CB1r-selective agonist
ACEA, or 100 nM of the CB2r-selective agonist JWH015. Control groups
of islets were incubated in the presence of 0.001% DMSO, the vehicle
used for preparation of ACEA and JWH015. Culture media replacement
and microscopic observation of the islets was performed daily.
2.3. Polymerase chain reaction (PCR)
Total RNA was isolated using RNeasy mini kits from groups of 150–
200 human islets previously treated for 2 or 5 days in the absence or
presence of ACEA or JWH015 except for quantiﬁcation of mRNAs
encoding ECS elements, where four groups of 150–200 human islets
were incubated overnight, without treatment, immediately after provi-
sion by the King's College Islet Transplantation Unit. RNA samples were
adjusted to obtain 20–50 ng/μl of cDNA by reverse transcription reac-
tions, as previously reported [24]. Real-time SYBR Green PCR ampliﬁca-
tions were performed with a LightCycler 480 96 well-plate system,
using the primers and conditions described in Table 1. Relativeexpression of mRNAs was determined after normalisation against 18s
rRNA as an internal reference gene, and calculated by the 2−ΔΔCt meth-
od [37].
2.4. Insulin and glucagon secretion
Human islets that had been maintained in culture for 2 or 5 days in
the absence or presence of 100 nM ACEA or 100 nM JWH015 were
washed then pre-incubated for one hour at 37 °C in 400 μl of physiolog-
ical buffer [38] containing 2 mM glucose. For measurements of insulin
and glucagon secretion groups of 5 and 10 islets respectively were
transferred to Eppendorf tubes and incubated for one hour at 37 °C in
500 μl of buffer supplemented with 16 mM glucose or 10 mM arginine.
Insulin and glucagon secreted from the islets in these static incubation
experiments was quantiﬁed by radioimmunoassay [17,39].
2.5. Insulin and glucagon content
Acidiﬁed ethanol (100 μl) was added to four groups of 10 human is-
lets that had been exposed for 2 or 5 days to DMEM (5.5 mM glucose)
alone or with DMEM supplemented with 100 nM of either ACEA or
JWH015. The islet samples were sonicated and stored at−20 °C until
radioimmunoassays were performed to measure insulin and glucagon
contents.
2.6. Caspase-3/7 activities
The extent of apoptosis of human islets previously maintained for 2
or 5 days in the absence or presence of cannabinoid agonists was deter-
mined by detection of caspase-3/7 activitieswith a luminometer follow-
ing cleavage of a proluminescent substrate (Z-DEVD-aminoluciferin), as
previously reported [40]. Apoptosis was induced in these experiments
by exposing ﬁve islets from each group to a cytokine cocktail (0.5 U/μl
IL-1β, 5 U/μl TNFα, and 5 U/μl IFNγ) for the ﬁnal 20 h of incubation.
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Data are expressed as means ± SEM of 3 or 4 individual experi-
ments. One-way and two-way ANOVA with Bonferroni's test were
used for analyses and differences between treatments were considered
statistically signiﬁcant at p b 0.05.3. Results
3.1. Relative mRNA expression of the endocannabinoid signalling elements
in human islets
Quantitative RT-PCR using human islet cDNAs indicated that the
mRNA encoding FAAH, an enzyme responsible for degradation of the
endocannabinoid AEA, was the most abundant component of the
endocannabinoid system in human islets. It was expressed at levels similar
to the mRNA coding for NAPE-PLD, which catalyses biosynthesis of AEA
from the membrane phospholipid N-acylphosphatidylethanolamine, and
both mRNAs were of similar abundance to preproglucagon mRNA
(Fig. 1). The mRNAs encoding the enzymes that regulate the synthesisFig. 1. Groups of 150–200 human islets were incubated overnight after isolation under
standard culture conditions and qPCR was used to quantify relative expression of
human islet mRNAs encoding preproinsulin (PPI), preproglucagon (PPG), and the
enzymes and receptors of the endocannabinoid system. Data are expressed as relative
percentage with respect to PPI mRNA levels, obtained from real-time PCR ampliﬁcation
values, normalised to 18s rRNA as an internal reference (means + SEM, n = 4).
Fig. 2. Quantiﬁcation of mRNAs encoding elements of the ECS in human islets after
maintenance for 2 (A) and 5 days (B) in DMEM (5.5 mM glucose) alone (open bars) or
supplemented with 100 nM ACEA (grey bars) or 100 nM JWH015 (black bars). Data are
expressed relative to the levels present in control islets in the absence of cannabinoid
receptor agonists and normalised to 18s rRNA levels in the same samples;
means + SEM, n = 4 experiments. Data were analysed by one-way ANOVA; *p b 0.05,
**p b 0.01 compared to the appropriate control.(DAGLα) and degradation (MAGL) of the othermajor endocannabinoid,
2-AG,were also detected in human islets but these, in particular DAGLα,
showed lower levels of expression than NAPE-PLD and FAAH mRNAs
(Fig. 1). Fig. 1 also indicates that CB1 and CB2 receptormRNAswere de-
tectable in human islets, but their expression levels were only approxi-
mately 0.1% of those of preproinsulin mRNA, which encodes the major
islet hormone.
Fig. 3. Acute, one hour insulin (panels A and C) and glucagon (panels B and D) secretion from human islets after maintenance for 2 (upper panels) or 5 (lower panels) days in DMEM
containing 5.5 mM glucose alone (control), or supplemented with 100 nM ACEA or 100 nM JWH015. Basal levels of insulin and glucagon secretion at 3 mM glucose are shown by the
open bars and the black bars show insulin secretion at 16 mM glucose (panels A and C) and glucagon secretion at 10 mM arginine panels B and D); means + SEM, n = 4 experiments.
Data were analysed by two-way ANOVA; *p b 0.05, **p b 0.01 versus the appropriate basal secretion, #p b 0.05 versus the appropriate control.
146 A. Vilches-Flores et al. / BBA Clinical 5 (2016) 143–1503.2. Effects of prolonged exposure to ACEA and JWH015 on ECS element
gene expression in human islets
Quantitative RT-PCR demonstrated that human islets exposed to a
CB1r (100 nM ACEA) or CB2r (100 nM JWH015) agonist for 2 or 5 days
affected expression of ECS elements. Thus, as can be seen from Fig. 2A,
stimulation of CB1r with ACEA (grey bars) induced signiﬁcant decreases
in NAPE-PLD, FAAH and MAGL mRNA levels at 2 days. While exposure
of islets to JWH015 for 2 days (black bars) also signiﬁcantly decreased
NAPE-PLDmRNA it did not affect FAAH orMAGL expression, but it did in-
duce signiﬁcant up-regulation of mRNAs encoding CB1r and CB2r. Expo-
sure of islets to ACEA for 5 days induced a 50% increase in CB1r mRNA
levels and a signiﬁcant reduction in DAGLαmRNA expression (Fig. 2B),
while 100 nM JWH015 caused at least 50% reductions inmRNAs encodingCB1r, FAAH and MAGL after 5 days. These gene expression studies indi-
cate that relatively short-term activation of CB1r by ACEA caused down-
regulation of mRNAs encoding enzymes involved in endocannabinoid
synthesis and degradation in human islets within 2 days, while chronic
activation of CB2 receptors over 5 days decreased mRNAs encoding can-
nabinoid degradation.
3.3. Effects of prolonged cannabinoid receptor activation on insulin and glu-
cagon secretion from human islets
Static incubation secretion experiments were performed to evaluate
whether chronic exposure to the cannabinoid agonists affected acute
glucose-stimulated insulin secretion (Fig. 3A and C) or acute arginine-
induced glucagon secretion (Fig. 3B and D) from human islets
Fig. 4. Insulin (panels A and C) and glucagon (panels B and D) hormone contents of human islets maintained for 2 (upper panels) or 5 (lower panels) days in the absence of cannabinoid
receptor agonists (open bars) or with 100 nM ACEA (grey bars) or 100 nM JWH015 (black bars). Data are expressed as ng/islet (means + SEM, n = 4). Data were analysed by one-way
ANOVA; *p b 0.05, **p b 0.01 versus the appropriate control.
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ACEA or JWH015 for 2 (upper panels) or 5 days (lower panels).
Islets that had been maintained in culture for 2 days and 5 days
showed signiﬁcant elevations in insulin secretion in response to
16 mM glucose (Fig. 3A and C, control), although basal and glucose-
stimulated insulin secretions were signiﬁcantly reduced after 5 days in
culture, compared to culture for 2 days. Basal insulin secretion at
3 mM glucose was signiﬁcantly increased in human islets after incuba-
tion for 2 days with 100 nM ACEA, but the magnitude of insulin secre-
tion at 16 mM glucose was not affected by 48 h pre-exposure to ACEA
(Fig. 3A). Islets that had been treatedwith ACEA for 5 days showed a re-
duced secretory response to 16 mMglucose, but there was still a signif-
icant elevation in insulin release over the low basal insulin output
(Fig. 3C). Treatment of human islets with 100 nM JWH015 for 2 daysand 5 days had no signiﬁcant effect on basal or glucose-stimulated insu-
lin secretion (Fig. 3A and C).
Islets responded to acute exposure to 10 mM arginine after 2 and
5 days in culture with signiﬁcant elevations in glucagon secretion
(Fig. 3B andD, control), although the extent of glucagon releasewas sig-
niﬁcantly reduced after 5 days. Pre-exposure of human islets to 100 nM
ACEA for 2 days signiﬁcantly elevated basal glucagon secretion without
modifying the amplitude of the glucagon secretory response to 10 mM
arginine (Fig. 3B), while islets incubated with ACEA for 5 days did not
show any alterations in basal or arginine-stimulated glucagon output
(Fig. 3D). Islets that had been exposed to JWH015 did not show a signif-
icant glucagon secretory response to 10mM arginine (Fig. 3B), but they
responded appropriately to arginine after they had been maintained in
the presence of JWH015 for 5 days (Fig. 3D).
Fig. 5.Micrographs of human islets maintained in culture for 2 (upper panels) or 5 (lower panels) days in DMEM containing 5.5 mM glucose (left) or supplemented with 100 nM ACEA
(middle) or 100 nM JWH015 (right). Micrographs are representative of 3 experiments using islets obtained from three different donors.
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and glucagon content in human islets
Since prolonged culture of human islets resulted in changes in insu-
lin and glucagon secretion, as shown in Fig. 3, further experiments were
carried out to quantify hormone content after 2 days and 5 days culture
in the absence and presence of ACEA and JWH015. It can be seen from
Fig. 4C (white bars) that maintenance of human islets in culture for
5 days resulted in signiﬁcant reduction in insulin content compared to
islets after 2 days in culture (Fig. 4A), but there was no signiﬁcant
change in glucagon content of the islets under the same conditions
(Fig. 4B andD,white bars). Exposure of human islets to the CB1r agonist
ACEA for 2 and 5 days had no effect on insulin content (Fig. 4A and C,
grey bars). However, ACEA induced a signiﬁcant increase in glucagon
content after 2 days (Fig. 4B, grey bars), and this could be responsible
for the elevated basal glucagon secretory response seen after mainte-
nance of islets in the presence of 100 nM ACEA for 2 days (Fig. 3B).
The CB2r agonist JWH015 caused a marked increase in insulin content
at 2 days (Fig. 4A, black bars). This increase was not sustained after
5 days of treatmentwith JWH015, and islet insulin levels under this con-
dition were not signiﬁcantly different from the reduced content seen in
the control islets. JWH015 also increased islet glucagon content after
2 days, but not at 5 days (Fig. 4B, black bars).3.5. Effects of chronic exposure to cannabinoid receptor agonists on human
islet morphology and apoptosis
The photomicrographs of human islets (Fig. 5) indicate that mainte-
nance for 2 days (upper panels) or 5 days (lower panels) in the absence
(left) or presence of 100 nM ACEA (middle) or JWH015 (right) did not
cause any major deleterious effects on integrity, although after 5 days
in culture all islets were generally less compact, with the loss of some
cells. This was associated with increased basal apoptosis after 5 days
compared to that seen at 2 days (Fig. 6A control, white bars versus
Fig. 6B). Evaluation of the effects of chronic exposure to cannabinoid ag-
onists on human islet cell caspase 3/7 activities was carried out in the
absence and presence of mixed cytokines (black bars) and these studies
indicated that pre-exposure to ACEA and JWH015 for 2 (Fig. 6A) or
5 days (Fig. 6B) had no effects on human islet cell apoptosis.4. Discussion
We, and others, have previously identiﬁed components of a local ECS
in human islets by PCR and immunohistochemistry [10,17,20,21,30], but
the relative expression of these elements has not been fully investigated.
Our observations indicate a relatively high mRNA expression of FAAH,
NAPE-PLD and MAGL in human islets, while DAGLα and both cannabi-
noid receptors show lower expression levels. The high levels of FAAH
mRNA that we detected in human islets is consistent with our earlier ob-
servations that this is the most abundant ECS mRNA in mouse islets [24],
as are our observations of low levels of CB1r, CB2r and DAGLα. It has pre-
viously been reported that CB1 expression is considerably higher than
CB2 in human islets [20], but this differential expression of the cannabi-
noid receptors was not conﬁrmed in the current study. We did ﬁnd
here that human islets express substantially more MAGL mRNA than
mouse islets do [17,24], suggesting that 2-AG levels are tightly controlled
in human islets throughMAGL-dependent degradation. Sincewhole islets
were used for mRNA puriﬁcation in these studies and our earlier work
with mouse islets [24], it was not possible to determine the distribution
and speciﬁc expression of the ECS elements in each islet cell type, but im-
munoﬂuorescence staining of humanpancreashas indicated the presence
ofMAGL, DAGLα, NAPE-PLD and FAAH in β-cells [10]. It is therefore likely
that the endogenous production, accumulation and degradation of
endocannabinoids are important in the modulation of islet functions.
Previous studies have demonstrated that expression of ECS compo-
nents is a dynamic process that is modiﬁed in response to high fat diet,
and high glucose concentrations are reported to increase AEA and 2-AG
synthesis in rodent and human islets [10,20]. In the current study the ef-
fects of 100 nM of CB1r (ACEA) and CB2r (JWH015) agonists were inves-
tigated, to provide a direct comparison with an earlier study in which we
had investigated the effects of chronic activation of cannabinoid receptors
inmouse islets [24]. The changes that we observed inmRNA levels in iso-
lated human islets of the enzymes involved in the synthesis and degrada-
tion of endocannabinoids suggest a negative feedback mechanism in the
presence of exogenous agonists, most likely to limit endogenous
endocannabinoid levels to minimise over-stimulation of the CB1 and
CB2 receptors. However, it is interesting that while chronic activation of
human islet cannabinoid receptors led to depletion ofmRNAs responsible
for regulation of endocannabinoid levels there was a simultaneous in-
crease in the mRNAs encoding CB1r and CB2r, which may have been a
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and 2-AG in the human islets following exposure to ACEA and JWH015
was not quantiﬁed in the current study, but it is possible that the up-
regulation of CB1r as well as CB2r mRNA following exposure to JWH015
for 2 days was a consequence of altered synthesis of the CB1r ligand
AEA by the islets. The role played by endogenous human islet
endocannabinoids in the patterns of ECS gene expression observed here
will be the subject of future work.
These changes in the ECS mRNAs in human islets in vitro support a
model of dynamic regulation of islet endocannabinoid content tomain-
tain the “on-demand” responses of islets to physiological and patholog-
ical stimuli [3,6,19,24,26,31,32]. However, the current study does not
provide direct information that islets in situ would necessarily respond
in the same manner as islets in vitro. Moreover, the use of whole islets,
while providing an appropriate physiological model, does not allow
identiﬁcation of the cells in which the alterations in ECS mRNAs occurs.
Although exposure of human islets to ACEA and JWH015 for 2 days
increased insulin and glucagon content, there were no marked effects
on acute secretion of these hormones, suggesting that islet stores of in-
sulin and glucagonwere enhanced, rather thanβ- orα-cell secretory ca-
pacity. Overall, maintenance of human islets with the cannabinoid
receptor agonists waswithout deleterious effects, either on the capacity
of islets to secrete insulin and glucagon in response to glucose and argi-
nine respectively, or in terms of islet cell viability. Our observations that
apoptosis was not enhanced by exposure of islets to CB1r or CB2r ago-
nists is in contrast to observations that acute and chronic exposure to
cannabinoids induces apoptosis in a number of cell types [5,41–43], in-
cluding islet β-cells [22]. However, there is also evidence supporting a
protective role of 2-AG and AEA in cell survival [44–47], and we have
previously reported that pre-exposure of mouse islets to 100 nM
ACEA or JWH015 for 7 days protects against cytokine-induced apoptosis
[24]. A similar protective effect was not observed in the current studies,
which may reﬂect the 5 day time-course of exposure here and 7 days
with mouse islets, or it may indicate species-dependent differences in
apoptotic signalling downstream of cannabinoid receptor activation in
mouse and human islets. Nonetheless, our data clearly demonstrate
that chronic treatment of human islets with 100 nM ACEA or JWH015
does not induce apoptosis. This apparent discrepancy with an earlier
study in islets [22] may be due to the use in that study of 25 μM 2-AG
and AEA to maximally reduce islet cell viability over 48 h, a concentra-
tion that is several orders ofmagnitude higher than detected in diabetes
[3], and considerably higher than those used in the current study.
5. Conclusion
In conclusion, we report that prolonged maintenance of isolated
human islets in the presence of cannabinoid CB1 and CB2 receptor ago-
nists modulates the gene expression of ECS components and promotes
short-term increases in islet insulin and glucagon content, but does
not exert deleterious effects on islet viability or function. Our results
suggest that over-activation of islet endocannabinoid receptors induces
an adaptation process through down-regulation of endogenous islet
cannabinoid levels, but the maintenance of islet viability and function
suggests that islet cell death and dysfunction do not play a role in the
metabolic defects arising from over-activation of the ECS in obesity
and diabetes. Thus, these data are consistent with the impairments in
glucose homeostasis observed following increased production of
endocannabinoids being a consequence of insulin resistance rather
than β-cell dysfunction or α-cell hypersecretion.Fig. 6. Caspase-3/7 activities in human islets after maintenance for 2 (panel A) or 5 (panel
B) days in DMEM containing 5.5 mM glucose alone (control) or supplemented with
100 nM ACEA or 100 nM JWH015. Apoptosis was induced by adding a cytokine cocktail
(0.5 U/ml IL1β, 5 U/ml TNFα, and 5 U/ml IFNγ) for the ﬁnal 20 h of incubation, shown
by the black bars. Data are expressed in luminescence units (means + SEM, n = 6 for
panel A, n = 4 for panel B). Data were analysed by two-way ANOVA; *p b 0.05 with
respect to basal apoptosis in the absence of cytokines.
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